On 13 April 2007, orphan designation (EU/3/07/444) was granted by the European Commission to Oxford Regulatory Solutions Ltd, United Kingdom, for pralatrexate for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).
The sponsorship was transferred to European Medical Advisory Services Limited, United Kingdom, in December 2007 and subsequently to Allos Therapeutics Limited, United Kingdom, in April 2010.
|Disease / condition||
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
|Date of first decision||
|EU designation number||
Sponsor's contact details
71 Knowl Piece
Hertfordshire SG4 OTY
Telephone: +44 1462 424 416
Telefax: +44 1462 600 453
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.